Press releases

To stay up to date with our development, sign up for a subscription.

Subscribe

Sedana Medical publishes its Annual Report for 2018

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announce that its Annual Report for 2018 has been published and is available on www.sedanamedical.com under Investors.

Notice of Annual General Meeting in Sedana Medical AB (publ)

Regulatory

Sedana Medical AB (publ) hereby convenes the Annual General Meeting 2018. The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting on Tuesday 28 May 2019 at 4 p.m. (CEST) at Erik…

The road to registration in the US clarified

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the US Food and Drug Administration (FDA) during a pre-IND meeting is positive about the combination registration of IsoConDa and AnaConDa in the US. Sedana Medical now has a clear…

Positive interim analysis in pivotal IsoConDa phase III study

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the results of the interim analysis for the company's pivotal phase III study aimed at getting the candidate drug IsoConDa (isoflurane) approved for inhalation sedation in intensive care…

Sedana Medical establishes sedation research foundation

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the establishment of the Sedana Medical Research Foundation, creating a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pati…

Sedana Medical’s nomination committee appointed

Regulatory

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 22, 2018, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…

Sedana Medical shows significant health-economic benefits with AnaConDa

Non-regulatory

Sedana Medical AB (publ) (Sedana Medical or the company) presents a health economic analysis at the European Conference for Health Economics and Outcomes Research 2018 (ISPOR) in Barcelona, showing clinical and economic benefits of inhaled isoflurane…

Sedana Medical receives approval for AnaConDa in Japan

Regulatory

Sedana Medical AB (publ) (Sedana Medical or the company) announces today that the company has received market approval for AnaConDa from the Ministry of Health, Labour and Welfare (MHLW) in Japan.  Through the approval, AnaConDa can now be marketed,…

Completed sale of shares in Sedana Medical AB (publ)

Regulatory

Sedana Medical AB (publ) (“Sedana Medical”) broadens the shareholder base through a secondary sale of existing shares by four insiders to Handelsbanken Fonder, Apus Capital, Norron Asset Management and Brohuvudet AB (the “Block Sale”). The Block Sale…